Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.

Sean M. Post; Vinod Pant; Hussein Abbas; Alfonso Quintás-Cardama

doi:10.18632/oncotarget.123

Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.

Sean M. Post, Vinod Pant, Hussein Abbas, Alfonso Quintás-Cardama

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

A T-to-G germline single nucleotide polymorphism in the promoter region of MDM2 (SNP309) has been reported to markedly accelerate tumor formation in humans suggesting that it may represent a powerful cancer predisposing allele. Since its first description in 2004, a large number of retrospective analyses involving a wide variety of human malignancies have been reported, showing conflicting results regarding the impact of Mdm2SNP309 status on cancer risk and response to cancer therapy. Here, we appraise the available information on the effect of Mdm2SNP309 in lymphoma and leukemia and discuss the factors that likely account for the conflicting results observed in the studies reported to date.

Original language	English (US)
Pages (from-to)	168-174
Number of pages	7
Journal	Oncotarget
Volume	1
Issue number	3
DOIs	https://doi.org/10.18632/oncotarget.123
State	Published - Jul 2010

ASJC Scopus subject areas

Oncology

Access to Document

10.18632/oncotarget.123

Cite this

@article{88b74f5adfd74f52bfe8d6bc689e3372,

title = "Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.",

abstract = "A T-to-G germline single nucleotide polymorphism in the promoter region of MDM2 (SNP309) has been reported to markedly accelerate tumor formation in humans suggesting that it may represent a powerful cancer predisposing allele. Since its first description in 2004, a large number of retrospective analyses involving a wide variety of human malignancies have been reported, showing conflicting results regarding the impact of Mdm2SNP309 status on cancer risk and response to cancer therapy. Here, we appraise the available information on the effect of Mdm2SNP309 in lymphoma and leukemia and discuss the factors that likely account for the conflicting results observed in the studies reported to date.",

author = "Post, {Sean M.} and Vinod Pant and Hussein Abbas and Alfonso Quint{\'a}s-Cardama",

year = "2010",

month = jul,

doi = "10.18632/oncotarget.123",

language = "English (US)",

volume = "1",

pages = "168--174",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals",

number = "3",

}

TY - JOUR

T1 - Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.

AU - Post, Sean M.

AU - Pant, Vinod

AU - Abbas, Hussein

AU - Quintás-Cardama, Alfonso

PY - 2010/7

Y1 - 2010/7

N2 - A T-to-G germline single nucleotide polymorphism in the promoter region of MDM2 (SNP309) has been reported to markedly accelerate tumor formation in humans suggesting that it may represent a powerful cancer predisposing allele. Since its first description in 2004, a large number of retrospective analyses involving a wide variety of human malignancies have been reported, showing conflicting results regarding the impact of Mdm2SNP309 status on cancer risk and response to cancer therapy. Here, we appraise the available information on the effect of Mdm2SNP309 in lymphoma and leukemia and discuss the factors that likely account for the conflicting results observed in the studies reported to date.

AB - A T-to-G germline single nucleotide polymorphism in the promoter region of MDM2 (SNP309) has been reported to markedly accelerate tumor formation in humans suggesting that it may represent a powerful cancer predisposing allele. Since its first description in 2004, a large number of retrospective analyses involving a wide variety of human malignancies have been reported, showing conflicting results regarding the impact of Mdm2SNP309 status on cancer risk and response to cancer therapy. Here, we appraise the available information on the effect of Mdm2SNP309 in lymphoma and leukemia and discuss the factors that likely account for the conflicting results observed in the studies reported to date.

UR - http://www.scopus.com/inward/record.url?scp=80054682401&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054682401&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.123

DO - 10.18632/oncotarget.123

M3 - Review article

C2 - 21301048

AN - SCOPUS:80054682401

SN - 1949-2553

VL - 1

SP - 168

EP - 174

JO - Oncotarget

JF - Oncotarget

IS - 3

ER -

Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this